S. Megnien

1.9k total citations
19 papers, 405 citations indexed

About

S. Megnien is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, S. Megnien has authored 19 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 8 papers in Hepatology and 6 papers in Surgery. Recurrent topics in S. Megnien's work include Liver Disease Diagnosis and Treatment (10 papers), Liver Diseases and Immunity (6 papers) and Diet, Metabolism, and Disease (3 papers). S. Megnien is often cited by papers focused on Liver Disease Diagnosis and Treatment (10 papers), Liver Diseases and Immunity (6 papers) and Diet, Metabolism, and Disease (3 papers). S. Megnien collaborates with scholars based in France, United States and Germany. S. Megnien's co-authors include Vlad Ratziu, Stephen A. Harrison, Brent A. Neuschwander‐Tetri, Veronica Miller, David E. Kleiner, Arun J. Sanyal, Elmer Schabel, Rémy Hanf, Bart Staels and Kris V. Kowdley and has published in prestigious journals such as Hepatology, Journal of Hepatology and Atherosclerosis.

In The Last Decade

S. Megnien

17 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Megnien France 7 297 211 117 97 68 19 405
Bert Van Den Bossche Belgium 5 266 0.9× 201 1.0× 93 0.8× 54 0.6× 133 2.0× 10 470
Beatriz Barranco-Fragoso Mexico 8 327 1.1× 228 1.1× 59 0.5× 69 0.7× 66 1.0× 13 432
B. Kutala France 4 370 1.2× 328 1.6× 92 0.8× 61 0.6× 91 1.3× 7 530
Lucia Parlati France 11 298 1.0× 208 1.0× 77 0.7× 64 0.7× 75 1.1× 35 434
Kyoko Yonemitsu Japan 6 296 1.0× 115 0.5× 88 0.8× 118 1.2× 95 1.4× 10 422
Nadege Gunn United States 10 439 1.5× 210 1.0× 82 0.7× 188 1.9× 159 2.3× 21 583
Zoe Boyer‐Díaz Spain 7 287 1.0× 218 1.0× 84 0.7× 51 0.5× 109 1.6× 10 426
A. Provenzano Italy 9 222 0.7× 144 0.7× 47 0.4× 63 0.6× 72 1.1× 15 379
Seita Kataoka Japan 13 229 0.8× 103 0.5× 47 0.4× 86 0.9× 88 1.3× 34 397
Stephanie A. Osganian United States 11 432 1.5× 210 1.0× 64 0.5× 184 1.9× 70 1.0× 13 529

Countries citing papers authored by S. Megnien

Since Specialization
Citations

This map shows the geographic impact of S. Megnien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Megnien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Megnien more than expected).

Fields of papers citing papers by S. Megnien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Megnien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Megnien. The network helps show where S. Megnien may publish in the future.

Co-authorship network of co-authors of S. Megnien

This figure shows the co-authorship network connecting the top 25 collaborators of S. Megnien. A scholar is included among the top collaborators of S. Megnien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Megnien. S. Megnien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Schattenberg, Jörn M., Albert Parés, Kris V. Kowdley, et al.. (2021). A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology. 74(6). 1344–1354. 125 indexed citations
3.
Cusi, Kenneth, Naim Alkhouri, Stephen A. Harrison, et al.. (2021). Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. ˜The œLancet. Gastroenterology & hepatology. 6(11). 889–902. 50 indexed citations
4.
Hanf, Rémy, Pierre Chaumat, Zouher Majd, et al.. (2019). SAT-299-Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2) in patients at risk of NASH. Journal of Hepatology. 70(1). e770–e770. 2 indexed citations
5.
Cheung, Amanda, Brent A. Neuschwander‐Tetri, David E. Kleiner, et al.. (2019). Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 70(5). 1841–1855. 59 indexed citations
6.
7.
Legry, Vanessa, Émeline Descamps, Benoît Noël, et al.. (2019). FRI-355-Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment. Journal of Hepatology. 70(1). e551–e551. 2 indexed citations
8.
Hanf, Rémy, Christine Pierre, John Brozek, et al.. (2018). Validation of NIS4 algorithm for detection of NASH at risk of cirrhosis in 467 NAFLD patients prospectively screened for inclusion in the RESOLVE-IT trial. Journal of Hepatology. 68. S115–S116. 1 indexed citations
9.
Walczak, Robert, Benoit Banga N’guessan, Émeline Descamps, et al.. (2018). Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model. Journal of Hepatology. 68. S352–S353. 8 indexed citations
10.
Siddiqui, Mohammad Shadab, Stephen A. Harrison, Manal F. Abdelmalek, et al.. (2017). Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 67(5). 2001–2012. 109 indexed citations
11.
Francque, Sven, Frédéric Texier, Vlad Ratziu, et al.. (2017). Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. Journal of Hepatology. 66(1). S110–S111. 1 indexed citations
12.
Ratziu, Vlad, S. Harrison, Benoît Noël, et al.. (2017). Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH. Journal of Hepatology. 66(1). S113–S113. 1 indexed citations
13.
Harrison, S., John Brozek, A. Roudot, et al.. (2017). A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH. Journal of Hepatology. 66(1). S110–S110. 4 indexed citations
14.
Sanyal, A., John Brozek, A. Roudot, et al.. (2016). A New Method including the Quantification of Circulating Mirnas Allows the Efficient Identification of Nash Patients at Risk who should be Treated. Journal of Hepatology. 64(2). S717–S717. 1 indexed citations
15.
16.
Francque, Sven, S.A. Harrison, A. Sanyal, et al.. (2016). Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis. Journal of Hepatology. 64(2). S499–S500. 1 indexed citations
17.
Ripoll, Christophe, et al.. (2009). Gastrointestinal tolerance to an inulin-rich soluble roasted chicory extract after consumption in healthy subjects. Nutrition. 26(7-8). 799–803. 29 indexed citations
18.
Megnien, S., et al.. (1997). 2.P.33 Long-term extension of the comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia. Atherosclerosis. 134(1-2). 123–123. 2 indexed citations
19.
Megnien, S., et al.. (1997). 2.P.32 Comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia. Atherosclerosis. 134(1-2). 123–123. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bert Van Den Bossche Breakdown of academic impact, for papers by Beatriz Barranco-Fragoso Breakdown of academic impact, for papers by B. Kutala Breakdown of academic impact, for papers by Lucia Parlati Breakdown of academic impact, for papers by Kyoko Yonemitsu Breakdown of academic impact, for papers by Nadege Gunn Breakdown of academic impact, for papers by Zoe Boyer‐Díaz Breakdown of academic impact, for papers by A. Provenzano Breakdown of academic impact, for papers by Seita Kataoka Breakdown of academic impact, for papers by Stephanie A. Osganian
Rankless by CCL
2026